Researchers developed a model to predict risk of TIPN in patients with early-stage cancer treated with a taxane regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results